Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Dose Escalation Study of SF1126, a PI3 Kinase (PI3K) Inhibitor, Given By Intravenous (IV) Infusion in Patients With Solid Tumors (SF112600106)

This study has been completed.
Sponsor:
Collaborator:
SignalRx Pharmaceuticals Inc.
Information provided by (Responsible Party):
Semafore Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT00907205
First received: May 20, 2009
Last updated: June 11, 2013
Last verified: June 2013